Javascript must be enabled to continue!
High-Throughput Human Gut Immune Co-Culture Model for Evaluating Inflammatory Bowel Disease Anti-Inflammatory Therapies
View through CrossRef
AbstractCurrent treatments for inflammatory bowel disease (IBD) are often ineffective long-term, as many patients ultimately become unresponsive to anti-inflammatory drugs. The need for improved therapeutics is urgent. Animal models utilized for drug development are limited by interspecies variability and poor translatability. However, most in vitro models lack the sophistication to model the key interplay of the immune system with the intestinal epithelium in line with the known role of the immune system in the etiology of the disease.To address this gap, we developed a primary intestinal epithelial cell co-culture system to incorporate elements of innate immune signaling. This system models immune-epithelial interactions using RepliGut®- Planar Transverse Colon cultured on a Transwell™ system with THP-1 derived macrophages in a receiver compartment of a 96-well plate. Epithelial barrier integrity and cell viability were maintained in co-culture with unstimulated macrophages. However, similar to the pathology associated with IBD, epithelial integrity was compromised in co-culture with LPS + IFN-γ pre-stimulated macrophages as evidenced by declining TEER and cell viability and increased inflammatory cytokine release. Cotreatment with anti-inflammatory IBD therapeutics adalimumab or tofacitinib mitigated these effects, demonstrating the model’s ability to replicate key inflammatory responses and prevention.Reproducibility and scalability of the model system further position the model for high-throughput screening of anti-inflammatory drugs, improving drug discovery, and accelerating the translation of new IBD therapies into clinical practice.HighlightsCo-culture model: RepliGut®- Planar Transverse Colon with THP-1 derived macrophagesHigh throughput and human-relevant model“Healthy” co-culture resembling healthy intestine“Inflamed” co-culture mimicking IBD innate inflammatory signalingPotential to screen anti-inflammatory drugs relevant to IBDGraphical AbstractGut-immune co-culture model simulating healthy and inflamed intestine.The immune co-culture model consists of mature differentiated primary human transverse colon epithelial cells cultured on a 96-well Transwell®plate with macrophage differentiated THP-1 cells (THP-1m) cultured in the receiver plate. In this configuration, the THP-1m are located basally to the epithelial cells, allowing for apical treatment in the transwell and basal treatment in the receiver plate. In the unstimulated state, intestinal cells and immune cells maintain a stable co-culture. Upon stimulation with LPS and IFN-y, both cell types initiate an inflammatory response that results in release of cytokines, loss of intestinal barrier integrity, and cytotoxicity.
Cold Spring Harbor Laboratory
Title: High-Throughput Human Gut Immune Co-Culture Model for Evaluating Inflammatory Bowel Disease Anti-Inflammatory Therapies
Description:
AbstractCurrent treatments for inflammatory bowel disease (IBD) are often ineffective long-term, as many patients ultimately become unresponsive to anti-inflammatory drugs.
The need for improved therapeutics is urgent.
Animal models utilized for drug development are limited by interspecies variability and poor translatability.
However, most in vitro models lack the sophistication to model the key interplay of the immune system with the intestinal epithelium in line with the known role of the immune system in the etiology of the disease.
To address this gap, we developed a primary intestinal epithelial cell co-culture system to incorporate elements of innate immune signaling.
This system models immune-epithelial interactions using RepliGut®- Planar Transverse Colon cultured on a Transwell™ system with THP-1 derived macrophages in a receiver compartment of a 96-well plate.
Epithelial barrier integrity and cell viability were maintained in co-culture with unstimulated macrophages.
However, similar to the pathology associated with IBD, epithelial integrity was compromised in co-culture with LPS + IFN-γ pre-stimulated macrophages as evidenced by declining TEER and cell viability and increased inflammatory cytokine release.
Cotreatment with anti-inflammatory IBD therapeutics adalimumab or tofacitinib mitigated these effects, demonstrating the model’s ability to replicate key inflammatory responses and prevention.
Reproducibility and scalability of the model system further position the model for high-throughput screening of anti-inflammatory drugs, improving drug discovery, and accelerating the translation of new IBD therapies into clinical practice.
HighlightsCo-culture model: RepliGut®- Planar Transverse Colon with THP-1 derived macrophagesHigh throughput and human-relevant model“Healthy” co-culture resembling healthy intestine“Inflamed” co-culture mimicking IBD innate inflammatory signalingPotential to screen anti-inflammatory drugs relevant to IBDGraphical AbstractGut-immune co-culture model simulating healthy and inflamed intestine.
The immune co-culture model consists of mature differentiated primary human transverse colon epithelial cells cultured on a 96-well Transwell®plate with macrophage differentiated THP-1 cells (THP-1m) cultured in the receiver plate.
In this configuration, the THP-1m are located basally to the epithelial cells, allowing for apical treatment in the transwell and basal treatment in the receiver plate.
In the unstimulated state, intestinal cells and immune cells maintain a stable co-culture.
Upon stimulation with LPS and IFN-y, both cell types initiate an inflammatory response that results in release of cytokines, loss of intestinal barrier integrity, and cytotoxicity.
Related Results
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
AbstractAim:Childhood onset inflammatory bowel disease is more aggressive and has rapidly progressive clinical course than adult inflammatory bowel disease. Early-onset inflammator...
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Abstract:
Background: ECF most frequently follows a complication of abdominal surgery, although a smaller number occur spontaneously in association with conditia
Background: Entero...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
P0050 4-Octyl Itaconate Protects Against Colitis by Modulating Neutrophil Function and Enhancing Intestinal Epithelial Barrier Integrity
P0050 4-Octyl Itaconate Protects Against Colitis by Modulating Neutrophil Function and Enhancing Intestinal Epithelial Barrier Integrity
Abstract
Background
Inflammatory bowel disease (IBD) is a complex gastrointestinal condition marked by immune system dysfunction...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Atypical Sigmoid Volvulus in an Adolescent: A Case Report and Literature Review
Atypical Sigmoid Volvulus in an Adolescent: A Case Report and Literature Review
Abstract
Introduction
Sigmoid volvulus is an underrecognized diagnosis with potentially fatal outcomes in adolescents; the current study aims to present an adolescent with mild sym...
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inf...

